A PHASE II TRIAL OF IMATINIB MESYLATE (GLEEVEC) IN PATIENTS WITH HIV RELATED

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标 主要目标：评估临床反应 次要目标 用免疫组织化学方法评价PDGF受体的抑制作用。 评价伊马替尼治疗前后的细胞因子谱。 评价伊马替尼在HIV患者中的药代动力学。 对伊马替尼治疗的原发和继发耐药机制进行评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Primary Objective: Evaluation of clinical response Secondary Objectives ¿ Evaluation of inhibition of PDGF receptor as determined by immunohistochemistry. ¿ Evaluation of cytokine profiles pre- and post-imatinib therapy. ¿ Evaluation of pharmacokinetic profile of imatinib in HIV patients. ¿ Evaluation of mechanisms of primary and secondary resistance to imatinib therapy.